<!DOCTYPE html>
<html lang="en">

<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/4.7.0/css/font-awesome.min.css">
    <link rel="preconnect" href="https://fonts.googleapis.com">
    <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
    <link href="https://fonts.googleapis.com/css2?family=Tinos:ital,wght@0,400;0,700;1,400;1,700&display=swap"
        rel="stylesheet">

    <link rel="preconnect" href="https://fonts.googleapis.com">
    <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
    <link
        href="https://fonts.googleapis.com/css2?family=Afacad+Flux:wght@100..1000&family=Tinos:ital,wght@0,400;0,700;1,400;1,700&display=swap"
        rel="stylesheet">

    <link rel="preconnect" href="https://fonts.googleapis.com">
    <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
    <link
        href="https://fonts.googleapis.com/css2?family=Lato:ital,wght@0,100;0,300;0,400;0,700;0,900;1,100;1,300;1,400;1,700;1,900&display=swap"
        rel="stylesheet">


    <link rel="preconnect" href="https://fonts.googleapis.com">
    <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
    <link href="https://fonts.googleapis.com/css2?family=Gemunu+Libre:wght@200..800&display=swap" rel="stylesheet">

    <link rel="stylesheet" href="../css/nav.css">
    <link rel="stylesheet" href="../css/footer_2.css">
    <link rel="stylesheet" href="../css/about.css">

    <title> Opthamology | Biointercept </title>

</head>

<body>
    <!-- <div class="alert">
        <p>
            <strong>Under Maintenance: Updating Webpages</strong>
        </p>
    </div> -->
    <div class="header">
        <div class="logo">
            <a href="../index.html"> <img src="../assets/biointercept_logo.png" style="height: 16rem;" /> </a>
        </div>
        <div class="nav-links">
            <a href="../about.html" class="">WHO WE ARE</a>
            <a href="../research-areas" class="has-dropdown">RESEARCH AREAS</a>
            <a href="../technology-and-data.html" class="has-dropdown">TECHNOLOGY & DATA
                <!-- <span class="arrow-down"></span> -->
            </a>
            <a href="../resources.html">RESOURCES</a>
            <a href="../contact-us.html" class="contact-btn">CONTACT US</a>
            <a href="../investor.html">INVESTORS</a>
        </div>
    </div>


    <h1> Opthamology </h1>
    <h3 class="subtitle-h3"><span class="subtitle-h3-blue">

            Innovative </span> 
        <span class="subtitle-h3-blue">

             </span>pthamological Treatment
        <span class="subtitle-h3-blue"> Expertise </span>

    </h3>


    <div class="hero-section">


        <div class="hero-image">
            <img src="./assets/opth_image.png" alt="Gene Illustration">
        </div>






<div class="hero-content">
    <p>
BioIntercept is pioneering new frontiers in ophthalmology by harnessing our proprietary exosome platform to address the
root causes of vision loss. Our research is intensely focused on developing therapies capable of crossing the
blood-retinal barrier to deliver neuroprotective and regenerative agents directly to affected tissues. By modulating
inflammatory responses and protecting vital retinal cells, we are developing novel approaches for diseases like glaucoma
and macular degeneration. This work is critical for creating a new generation of treatments aimed not just at slowing
progression, but at preserving and potentially restoring sight.
    </p>


    <h3 class="subtitle-h3" style="text-align: left; justify-content: left;"><span class="subtitle-h3-blue">
            Scientific & Clinical Rationale
        </span>
    </h3>
    <p style="text-align: left;justify-content: left;">
        Our exosome-based platform shows
        significant promise in pulmonary
        indications where inflammation, epithelial
        injury, and immune dysregulation play
        central roles:

    <ul style="justify-content: left; text-align:left; font-size:16px;">
        <li>Promotion of neovascularization</li>
        <li>Enhanced cardiomyocyte survival via miR-126, miR-210</li>
        <li>Clear clinical endpoints through LVEF and BNP measurements</li>
        <li>VEGF modulation</li>
        <li>Endothelial stabilization in diabetic retinopathy</li>
        <li>Support for age-related visual improvement</li>
        <li>Feasible topical/periocular delivery</li>
        <li>Well-defined regulatory endpoints (OCT, ERG)</li>

    </ul>



    </p>

    <p>

        Exosomes demonstrate VEGF modulation and endothelial stabilization in
        diabetic retinopathy. Topical/periocular delivery is feasible and regulatory
        endpoints (OCT, ERG) are well defined.
    </p>

    <br>


            Our talented team at <span class="content-blue"> Biointercept Biotechnology </span>
            delivers high quality services to ensure you meet your targeted results.
            
            </p>
            
            <h3 class="subtitle-h3">
                Reach out to us to
                <span class="subtitle-h3-blue"> learn more: </span>
            </h3>
            <a href="../contact-us.html" class="button">CONTACT US</a>
            </div>

</div>

            <!-- <p>


                Biointercept is at the forefront of oncology and hematology research, leveraging cutting-edge
                technologies to
                revolutionize cancer treatment and blood disorder management. Our scientists employ advanced techniques
                with our proprietary exosome technology
                to help solve oncologies most challenging problems.
                By integrating multi-omics data with sophisticated bioinformatics, we are uncovering
                crucial insights into cancer progression, drug resistance mechanisms, and personalized treatment
                strategies, paving the
                way for more effective and less toxic interventions.
                <br />
                Cancer remains a leading cause of death globally, with the oncology therapeutics market
                exceeding $150 billion annually. Exosomes present a dual opportunity in oncology spanning
                both therapeutic and diagnostic applications.
            </p>



            <h3 class="subtitle-h3" style="text-align: left; justify-content: left;"><span class="subtitle-h3-blue">
                    Therapeutic Applications
                </span>
            </h3>


            <p>


            <ul style="justify-content: left; text-align:left; font-size:16px;">
                <li><span class="content-blue">Targeted Drug Delivery:</span>
                    Exosomes can be engineered to deliver chemotherapeutic
                    agents, small molecule inhibitors, or RNA-based therapies directly to tumor cells while
                    sparing healthy tissues
                </li>
                <br />

                <li><span class="content-blue">Immunomodulation:</span>
                    Exosomes from dendritic cells or engineered with tumor antigens
                    can stimulate anti-tumor immune responses </li>
                <br />
                <li><span class="content-blue">Gene Therapy Delivery: </span>
                    Delivery of therapeutic mRNAs, siRNAs, or CRISPR-Cas9
                    components to cancer cells</li>
                <br />
                <li><span class="content-blue">Market Opportunity: </span>
                    The total addressable market for our platform therapies is $280
                    billion, with immediate addressable market of $220 billion in
                    Regenerative Medicine across 6 critical need indications.</li>


            </ul>

            </p>

            <h3 class="subtitle-h3" style="text-align: left; justify-content: left;"><span class="subtitle-h3-blue">
                    Key Advantages
                </span>
            </h3>
            <p>

                This therapeutic platform demonstrates significantly enhanced penetration into solid tumors,
                outperforming
                conventional
                antibodies and nanoparticlses. Crucially, it possesses the unique ability to cross the blood-brain
                barrier, opening
                new
                avenues for effective brain tumor treatment. This precise targeting capability leads to substantially
                reduced
                off-target
                toxicity compared to conventional chemotherapy, improving patient safety. The platform's high degree of
                specificity
                is
                achieved by engineering exosome surface proteins. This versatility allows for multiple, simultaneous
                targeting
                strategies to be deployed. Ultimately, these combined attributes create a more potent and safer approach
                to treating
                historically challenging diseases.
            </p>



            <br /><br />

            <br /><br /> -->



    </div>
    <footer class="footer">
        <hr class="footer-divider">

        <div class="footer-content">
            <div class="footer-info">
                <p><strong>Biointercept Biotechnology Inc.</strong></p>

            </div>

            <div class="footer-links">
                <p>Â© 2025 Biointercept, All Rights Reserved |
                    <a href="../maintenance.html">Privacy Policy</a> |
                    <a href="../maintenance.html">Accessibility Statement</a> |

                    <a href="../maintenance.html">Terms of Use</a> |
                    <a href="../maintenance.html">Sitemap</a>
                </p>
            </div>

            <div class="social-icons">
                <a href="../maintenance.html" class="fa fa-facebook"></a>
                <a href="https://www.linkedin.com/company/Biointercept-biotech/" class="fa fa-linkedin"></a>

            </div>
        </div>
    </footer>


</body>

</html>